Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Troubadour Resources Inc. (V:TR)

Business Focus: Coke Coal Mining

Jul 21, 2021 09:00 am ET
Troubadour Drills High-Grade Polymetallic Veins and Discovers Gold-Rich Bulk Tonnage System at the Texas Project
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to provide drill results from its 2,093 m Phase 1 drill program at the 2,186-hectare Texas property located near the town of Beaverdell in southern B.C.
Jun 17, 2021 09:00 am ET
Troubadour Provides Update on Status of Drill Results for Texas Gold Project
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to provide an update on the status of drill results from phase 1 drilling and announce plans to mobilize a geological crew to the Texas Gold project in the coming weeks.
May 27, 2021 09:00 am ET
Troubadour Completes Phase 1 Drilling at the High-Grade Texas Gold Project
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to provide an update on its drilling program at the 2,186-hectare Texas property located near the town of Beaverdell in southern B.C.
May 04, 2021 09:00 am ET
Troubadour Commences Drilling at the High-Grade Texas Gold Project
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has commenced its planned drill program on the 2,186-hectare Texas property located near the town of Beaverdell in southern B.C.
Apr 20, 2021 09:00 am ET
Troubadour Signs Drill Contract for Texas Project
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has secured a drill rig to conduct the upcoming drill program on its 2,186-hectare Texas property located near the town of Beaverdell in southern B.C.
Apr 13, 2021 07:45 pm ET
Early Warning Press Release Regarding Investment in Troubadour Resources Inc.
CALGARY, AB / ACCESSWIRE / April 13, 2021 / Mr. Ryan Kalt reports that he today acquired through Kalt Industries Ltd., on a beneficial indirect basis, an aggregate of 150,000 common shares (the "Open-Market Common Shares") of Troubadour Resources Inc. (TSXV:TR)("Troubadour" or the "Company") by way of open-market facilities of the TSX Venture Exchange (the "Triggering Acquisition").
Mar 31, 2021 09:00 am ET
Troubadour Completes Airborne Survey and Stakes Additional Ground at Amarillo
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has completed its planned 610 line-kilometer airborne VTEM and magnetometer survey over the Company's 100% owned Amarillo Copper Project, southwestern BC.
Mar 26, 2021 01:28 pm ET
Troubadour Closes Oversubscribed Private Placement Financing of $720,000
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2021) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has closed its previously announced oversubscribed private placement financing (see news release dated March 12, 2021 and March 22, 2021) by issuing 6,000,000 units (each a "Unit") at a price of $0.12 per Unit for gross proceeds of $720,000 (the "Financing").
Mar 22, 2021 09:15 am ET
Troubadour Increases Private Placement Financing to $720,000
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce due to an oversubscription and strong demand that it has increased its previously announced private placement financing (see news release dated March 12, 2021) to 6,000,000 units (each a "Unit") at $0.12 per Unit for gross proceeds of up to $720,000 (the "Offering").
Mar 12, 2021 01:02 pm ET
Troubadour Announces $600,000 Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce a private placement financing of up to 5,000,000 units (each a "Unit") at $0.12 per Unit for gross proceeds of up to $600,000 (the "Offering").
Mar 10, 2021 09:00 am ET
Troubadour Reports Overlimit Bonanza Grade Results from the Texas Project
Vancouver, British Columbia--(Newsfile Corp. - March 10, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce the overlimit gold, silver and base metal results from Phase 1 fieldwork at its 2,186-hectare Texas property located in the Greenwood Mining Division of southern B.C.
Mar 03, 2021 09:00 am ET
Troubadour to Fly High-Resolution Airborne Survey at Amarillo
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has contracted Geotech Ltd. of Aurora, Ontario to conduct an airborne VTEM and magnetometer survey over the Company's 100% owned Amarillo Copper Project, southwestern BC.
Feb 25, 2021 09:00 am ET
Troubadour Reports Bonanza-Grade Gold Results from Phase 1 Rock Sampling at the Texas Project
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce rock sampling results from the Phase 1 exploration program completed on its 2,186 hectare Texas property located in the Greenwood Mining Division of southern B.C.
Feb 04, 2021 09:00 am ET
Troubadour Identifies High Grade Gold and Silver Target Areas at the Texas Project
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC PINK: TROUF) (the "Company") is pleased to announce geochemical and geophysical results from the Phase 1 exploration program completed on its 2,186 hectare Texas property located in the Greenwood Mining Division of southern B.C.
Jan 14, 2021 09:00 am ET
Troubadour Receives Five-Year Drill Permit for the Texas Project
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has been granted a five-year area-based exploration permit for its 2,186 hectare Texas property located in the Greenwood Mining Division of Southern B.C.
Dec 21, 2020 05:18 pm ET
Troubadour Closes Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 21, 2020) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce the closing of a fully subscribed private placement announced on December 1, 2020.
Dec 01, 2020 07:07 pm ET
Troubadour Announces a Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it proposes to close a fully subscribed private placement.
Dec 01, 2020 09:00 am ET
Troubadour Completes Phase 1 Work Program at Texas Gold Project
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTCQB: TROUF) (the "Company") is pleased to announce that it has completed its Phase 1 exploration program on its 2186-hectare Texas property located in the Greenwood Mining District of Southern B.C.
Oct 21, 2020 09:00 am ET
Troubadour Stakes Additional Ground at Texas and Mobilizes Field Crew
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has acquired by staking an additional 420 hectares (ha) of highly prospective ground contiguous to its Texas property located in the Greenwood Mining District of Southern B.C. The Texas property now covers an area of 2,186 ha.
Oct 07, 2020 09:00 am ET
Troubadour Signs Option to Acquire 100% Interest in Bonanza Grade Gold Project, Southern BC
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that it has entered into an option agreement with 1218802 B.C. LTD. , an arm's length vendor (the "Vendor"), to acquire a 100% interest in the 1,766 ha Texas property located in the Greenwood Mining District in Southern B.C.
Sep 03, 2020 06:25 pm ET
Troubadour AGM Update
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") wishes to announce that in light of the ongoing public health concerns related to COVID-19 and in order to comply with the measures imposed by federal and provincial governments, the Company is encouraging shareholders and others not to attend the meeting in person. Shareholders are urged to vote on the matters before the meeting by proxy and to listen to the meeting via telephone conference at Toll-free 1-888-299-2873 or International +1 (647) 317-4262. All callers will be prompted to enter the following meeting ID upon entering the conference: 834-373-355.
Feb 27, 2020 09:00 am ET
Troubadour Announces 2020 Exploration Plans
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce 2020 exploration plans at the Company's 100% owned Amarillo Copper Project, Southwestern BC.
Jan 16, 2020 09:00 am ET
Troubadour Drills Extensive Porphyry Mineralization and Alteration at the Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2020) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce that the recently completed four hole, 1,075m drill program on the Company's 100% owned Amarillo Project intersected large intervals of mineralization and alteration indicative of an alkalic porphyry system.
Nov 18, 2019 10:00 am ET
Troubadour Completes Drill Program and Stakes Additional Ground at the Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC PINK: TROUF) (the "Company") is pleased to announce the completion of the drill program on the Company's 100% owned Amarillo Cu-Au Porphyry project in southwestern B.C. ("Amarillo") as announced on October 28, 2019.
Nov 01, 2019 04:30 pm ET
Troubadour Closes Financing
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce the closing of the financing announced on October 9, 2019.
Oct 28, 2019 10:00 am ET
Troubadour has Commenced Drill Program at the Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - TROUBADOUR RESOURCES INC. (the "Company") (TSXV: TR) (OTCQB: TROUF) is pleased to announce that drilling has commenced on the Company's 100% Amarillo Cu-Au Porphyry project in southwestern B.C. ("Amarillo").
Oct 09, 2019 04:30 pm ET
Troubadour Resources Announces $257,500 Financing
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") announces that it has arranged a non-brokered private placement financing of 5,150,000 units ("Units") of the Company at a price of $0.05 per Unit for gross proceeds of $257,500 (the "Financing").
Jun 12, 2019 09:00 am ET
Troubadour Mobilizes Field Crews to Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is pleased to announce it has mobilized field crews to its 100% owned Amarillo Cu-Au Porphyry project in southwestern B.C. ("Amarillo"). The planned field work will consist of prospecting, geochemical sampling, geological mapping and a drone survey over high priority areas to further define drill targets for a follow-up exploration drill program commencing in the coming weeks. The Amarillo remains the Troubadour's flagship project and will be the focus of the Company's exploration efforts for the foreseeable future.
Jun 07, 2019 09:00 am ET
Troubadour to Focus on Amarillo Project, Southwestern B.C., Elects Not to Proceed with the Acquisition of thePrivateer High-Grade Gold Project, Zeballos, B.C.
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC Pink: TROUF) (the "Company") is providing notice that it will no longer be proceeding with the acquisition of Privateer Gold Mines as announced on March 5, 2019.
May 06, 2019 09:00 am ET
Troubadour Provides Update on the Privateer High-Grade Gold Project, Zeballos, B.C.
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTCQB: TROUF) (the "Company") is pleased to provide an update on the Company's ongoing activities during its due diligence period as part of its right to acquire a 100% interest in the Privateer Gold Property located on the northwest coast of Vancouver Island, B.C., near the town of Zeballos.
Mar 26, 2019 09:00 am ET
Troubadour Provides Update on the Privateer High-Grade Gold Project, Zeballos, B.C.
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (OTC PINK: TROUF) (the "Company") is pleased to provide an update on the progress of its due diligence of the Privateer Gold Property (formerly the Surespan Gold Property) located on the northwest coast of Vancouver Island, B.C., near the town of Zeballos.
Mar 14, 2019 05:08 pm ET
IIROC Trading Resumption - TR; NGEN; ALAB.P
VANCOUVER, March 14, 2019 /CNW/ - Trading resumes in:
Mar 11, 2019 04:25 pm ET
Troubadour Signs Letter of Intent to Acquire Historic Zeballos High-Grade Gold Mining Camp, B.C.
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") announces an addition to its news release dated March 5, 2019 in order to include a proposed private placement financing of $2,000,000. The news release is amended and restated in its entirety below:
Mar 05, 2019 08:00 am ET
Troubadour Signs Letter of Intent to Acquire Historic Zeballos High-Grade Gold Mining Camp, B.C.
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") is pleased to announce that it has signed a letter of intent with Surespan Ltd. (the "Shareholder" or "Surespan") and its wholly owned subsidiary, Privateer Gold Ltd. (the "Target" or "Privateer Gold") granting an option to the Company to acquire all of the issued and outstanding shares of Privateer Gold. Privateer Gold is the owner of the Surespan Gold Property, which encompasses the historic Zeballos high-grade gold mining camp ("Zeballos" or the "Property"), on the northwest coast of Vancouver Island, B.C.
Mar 04, 2019 06:43 am ET
IIROC Trading Halt - TR
VANCOUVER, March 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 15, 2019 10:00 am ET
Troubadour to Resume and Expand Drilling at the Copper, Molybdenum, Gold Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2019) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") is pleased to provide an update on the planning and timing of the Company's resumption and expansion of drilling at its 100% owned Amarillo Project located approximately 30 kilometres west of the town of Peachland, British Columbia.
Jan 08, 2019 10:00 am ET
Troubadour Drill Program Update at the Copper, Molybdenum, Gold Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2019) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") is pleased to provide an update on the Company's maiden drill program at its 100% owned Amarillo Project located approximately 30 kilometres west of the town of Peachland, British Columbia.
Dec 17, 2018 10:25 pm ET
Troubadour Announces Results of AGM
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2018) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") is pleased to announce the results of its Annual General Meeting of shareholders held December 17, 2018, in Vancouver, B.C. The shares represented at the meeting were 17.54% of the issued shares with all motions receiving unanimous support by the Company shareholders including the following:
Dec 06, 2018 08:30 am ET
Troubadour Commences Drilling at the Amarillo Project, Southwestern B.C.
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2018) -  TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") is pleased to announce the commencement of the Company's maiden drill program at its 100% owned Amarillo Project located approximately 30 kilometres west of the town of Peachland. The 2,000 metre program will focus on the Trench Anomaly that the Company believes to be the location of a historic trench, which was sampled in the 1960s and returned grades of 0.87% copper over a 125 metre length(1).
Nov 08, 2018 08:30 am ET
Troubadour Adds a Third Highly Prospective Porphyry Target and Maiden Drill Program on Track to Start at Amarillo
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2018) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") announces a third highly prospective drill target, the 'Cap Anomaly', identified 1.6 kilometres north of the Trench Anomaly (detailed in a Company news release dated Sept. 12, 2018) and the Company's upcoming maiden drill program, focusing on the Trench Anomaly, is on track and targeted for completion by the end of 2018.
Oct 22, 2018 08:40 pm ET
Troubadour Resources Closes $510,000 Financing
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") announces that, further to its news release of October 2, 2018, the Company has closed it non-brokered private placement financing of 4,250,000 units ("Units") of the Company at a price of $0.12 per Unit for gross proceeds of $510,000 (the "Financing").
Oct 03, 2018 04:30 pm ET
Troubadour Resources Announces $510,000 Financing
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2018) - TROUBADOUR RESOURCES INC. (TSXV: TR) (the "Company") announces that it proposes to complete a non-brokered private placement financing of up to 4,250,000 units ("Units") of the Company at a price of $0.12 per Unit for gross proceeds of $510,000 (the "Financing").
Sep 12, 2018 09:00 am ET
IP Survey Lights Up Extensive 'Trench Zone' Anomaly Over 1 Km in Size at Troubadour Resources' Amarillo Project, Southwestern BC
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2018) - Troubadour Resources Inc. (TSXV: TR) (the "Company") is pleased to announce the results of its recently completed 38.9 km 3D Induced Polarization ("IP") geophysical survey on its 100% owned Amarillo Project located in southwestern British Columbia, Canada.
Jul 19, 2018 08:30 am ET
Troubadour Resources Completes Phase 1 Exploration Program at Amarillo and Increases Land Holdings
Vancouver, British Columbia--(Newsfile Corp. - July 19, 2018) - Troubadour Resources Inc. (TSXV: TR) (the "Company") is pleased to announce that it has completed Phase 1 of its 2018 exploration program on its 100% owned Amarillo Project located in southwestern British Columbia, Canada.
Jun 07, 2018 10:06 pm ET
Troubadour Resources Inc. Completes Listing on the TSXV as a Tier 2 Mining Issuer and Will Commence Trading on June 11, 2018
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2018) - Troubadour Resources Inc. (TSXV: TR) (the "Company") is pleased to announce that it will list as a Tier 2 mining issuer on the TSX Venture Exchange ("TSX-V") on June 11, 2018 under the trading symbol "TR".
Mar 09, 2018 07:00 am ET
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the year ended December 31, 2017.
Jan 31, 2017 07:00 am ET
Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing 10-cohort Phase 1b study in patients with relapsed or refractory hematologic malignancies.
Jan 31, 2017 06:58 am ET
Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621...
Dec 03, 2016 12:00 pm ET
Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with relapsed or refractory hematologic malignancies, at the American Society of Hematology (ASH) 58(th) Annual Meeting in San Diego.
Dec 03, 2016 11:58 am ET
Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients...
Nov 29, 2016 07:00 am ET
Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH
Trillium Therapeutics Inc. (TSX: TR)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego. Trillium will present initial clinical data from its ongoing TTI-621 hematologic malignancy Phase 1 trial at ASH.
Nov 29, 2016 06:58 am ET
Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH
Trillium Therapeutics Inc. (TSX:TR)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on...
Nov 10, 2016 06:58 am ET
Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of Hematology (ASH) annual meeting in December Phase 1 trial with TTI-621 in solid tumors open for enrollment Cash totaled $55.6...
Nov 03, 2016 07:00 am ET
Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress at several upcoming conferences in 2016.
Nov 03, 2016 06:58 am ET
Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress at several upcoming...
Nov 02, 2016 07:00 am ET
Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies. As part of the advancement, the company provides the following study updates:
Nov 02, 2016 06:58 am ET
Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose...
Aug 31, 2016 07:00 am ET
Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral fellowship program to help young research scientists transition from their academic training to rewarding careers in the biopharmaceutical industry.
Aug 31, 2016 06:58 am ET
Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral fellowship program to...
Aug 23, 2016 07:00 am ET
Trillium Therapeutics to Present at Investor and Scientific Conferences in September
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.
Aug 23, 2016 06:58 am ET
Trillium Therapeutics to Present at Investor and Scientific Conferences in September
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and...
Aug 17, 2016 07:00 am ET
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides. Patient enrollment is anticipated to commence by the end of the year. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing Phase
Aug 17, 2016 06:58 am ET
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance...
Aug 12, 2016 07:00 am ET
Trillium Reports Second Quarter 2016 Financial Results
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and six months ended June 30, 2016.
Aug 12, 2016 06:58 am ET
Trillium Reports Second Quarter 2016 Financial Results
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and six months...
Jun 07, 2016 07:00 am ET
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology Association 21(st) Annual Congress, to be held in Copenhagen from June 9-12.
Jun 07, 2016 06:58 am ET
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology...
May 31, 2016 07:00 am ET
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting of shareholders held on May 27, 2016. The results of the director elections were as follows:
May 31, 2016 06:58 am ET
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting of shareholders held on...
May 18, 2016 05:00 pm ET
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting
Trillium Therapeutics Inc. (TSX: TR) (NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 3-7.
May 18, 2016 04:58 pm ET
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting
Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress...
May 13, 2016 07:00 am ET
Trillium Reports First Quarter 2016 Financial Results
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2016.
May 13, 2016 06:58 am ET
Trillium Reports First Quarter 2016 Financial Results
Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March...
Mar 23, 2016 07:00 am ET
Trillium Adopts Advance Notice By-Law Amendment
Trillium Therapeutics Inc. (NASDAQ: TRIL) (TSX: TR) a clinical immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its board of directors (Board) has adopted amendments to its...
Mar 10, 2016 09:00 am ET
Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program
Trillium Therapeutics Inc. (NASDAQ: TRIL) (TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration agreement with University Health Network and the Hospital for Sick Children to fund and undertake a research program entitled "SIRPaFc: Translating Genomics Research Into a Novel Cancer Immunotherapy." Importantly, this project has been approved for funding by Genome Canada under the Genomic Applications Partnership Program (GAPP). In addition, The Ontario Ministry of
Mar 09, 2016 05:30 pm ET
Trillium Reports 2015 Financial and Operating Results
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reports financial results for the year ended December 31, 2015 and provides a corporate update.
Mar 08, 2016 07:00 am ET
Trillium to Present at the Cowen and Company 36th Annual Health Care Conference
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Bob Uger, Ph.D., Chief Scientific Officer will present at the Cowen and Company 36th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on Wednesday, March 9th at 11:20 am.
Jan 28, 2016 08:00 am ET
Trillium Therapeutics Acquires Fluorinov Pharma
Combined entity creates strong foundation for leading Canadian immuno-oncology company
Jan 28, 2016 08:00 am ET
Trillium Therapeutics Acquires Fluorinov Pharma
Combined entity creates strong foundation for leading Canadian immuno-oncology company